ADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All

Tuesday, September 8, 2026Kathy VuksanajView original

The HiBiT Target Cell Killing (TCK) platform, with off-the-shelf, mix-and-match components, measures four killing mechanisms for broad immunotherapy modality assessment.

The post ADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All appeared first on GEN - Genetic Engineering and Biotechnology News.